Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial

This article has no abstract
Epistemonikos ID: 0b294e48cfca5f5855402ed75ebe7f8f1269cd38
First added on: Feb 15, 2025